#Netherlands #Amsterdam #iOnctura #roginolisib #uveal melanoma

iOnctura's Groundbreaking Progress in Uveal Melanoma Research

Recent Developments
On December 11, 2024, iOnctura, a clinical-stage biopharmaceutical firm, reported an important update regarding its lead candidate, roginolisib, a treatment targeting uveal melanoma. Following the completion of its Phase I DIONE-01 study, the results demonstrate favorable clinical activity and long-term safety, setting the stage for further evaluation in the upcoming Phase II OCULE-01 study.

The DIONE-01 study included two components; the first evaluated various doses of roginolisib in patients with previously treated cancers, while the second focused directly on 20 patients with uveal melanoma. Notably, the findings showed a median overall survival (OS) of 16 months in these patients, which was significantly higher than the median of 7 months reported in historical controls using standard immunotherapies. Moreover, the treatment was well-tolerated with fewer than 7% experiencing serious adverse events, marking a substantial improvement compared to earlier iterations of PI3Kδ inhibitors.

Roginolisib: A Unique Modulator
Roginolisib operates as an allosteric modulator of PI3Kδ, distinguished by its unique chemical structure and precise binding mechanism. This innovative design allows for a targeted approach that minimizes toxicity, making it exceptionally beneficial for patients with uveal melanoma, a rare but aggressive form of cancer. Given the escalating market interest predicted to reach $9.56 billion by 2032, the implications for this treatment are significant.

Catherine Pickering, CEO of iOnctura, expressed enthusiasm regarding the DIONE-01 results, emphasizing that the study's data supports the progression of roginolisib into the crucial Phase II segment of testing. "This study not only underscores the drug's potential but also offers hope for patients grappling with advanced uveal melanoma and other challenging cancers."

Expert Insights
Professor Michele Maio from the University of Siena, who leads the investigations on roginolisib, highlighted the positive indications of the treatment in future studies. He noted that the patients treated with roginolisib demonstrated prolonged disease stabilization without major side effects, maintaining a quality of life amidst ongoing treatment.

Next Steps
Site activation for the Phase II OCULE-01 study is currently underway. This phase will compare roginolisib against the investigator's choice in patients who require second-line treatment or beyond for uveal melanoma. The focus is not solely on survival rates but also the sustainability of the patients' quality of life – a crucial metric in cancer therapy.

Conclusion
iOnctura stands at a pivotal point in cancer therapy advancements, particularly in hard-to-treat varieties such as uveal melanoma. The upcoming results from the Phase II study will seek to validate the promising findings from DIONE-01 and could significantly impact cancer treatment protocols. As the company continues to push boundaries in treating neglected cancers through targeted therapies, the medical community watches with keen interest, eager to see how these developments unfold in the near future.

About iOnctura
Headquartered in Amsterdam, iOnctura is dedicated to developing innovative oral small molecules directed at challenging cancers with limited treatment options, solidifying its reputation as a pioneer in biopharmaceutical advancements. With a robust pipeline that expands beyond roginolisib, the company is positioned to change the landscape of cancer therapy for patients worldwide.